Top Story

FDA approves Fasenra for eosinophilic asthma maintenance therapy

November 15, 2017

The FDA has approved Fasenra for additional maintenance treatment of severe eosinophilic asthma in patients 12 years and older, according to the manufacturer release.

The approval of Fasenra (benralizumab, AstraZeneca) stems from the results of a program of studies, which included phase 3 exacerbation trials and a phase 3 oral corticosteroid-sparing trial. The respiratory biologic, which diminishes eosinophils within 24 hours, has not been approved for the treatment of other eosinophilic conditions, or the relief of acute bronchospasms or status asthmaticus.

In the Journals

Recommendations inconsistent in pediatric asthma guidelines

November 8, 2017
Although national and international guidelines for the treatment of pediatric bronchiolitis have many similarities, less agreement is found in guidelines for the
In the Journals

Obesity linked to repeated hospital admissions in children with asthma

November 6, 2017
Obesity was a risk factor for repeated hospital admissions in children with asthma, according to findings recently published in Pediatric Allergy and Immunology.
Meeting News

Spirometry underused in primary care

October 31, 2017
BOSTON — Only slightly more than half of all patients presenting to primary care providers with asthma underwent spirometry for diagnosis, according to a presenter…
More Headlines »
Feature Article

Manifestations of Food Allergy in Infants and Children

Pediatric Annals, August 2008, Volume 37 Issue 8
Parents frequently report that their children have adverse reactions to foods. Pediatricians must be familiar with the…
More »
Meeting News Coverage

VIDEO: Omalizumab potential option for virus induced exacerbations of asthma

February 25, 2015
More »